Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion type Assertion NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_head.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion description "[The 5-year survival rates were 57% for esophageal cancer patients with HER2 amplification compared with 32% without, but the difference in overall survival was not significant (P�=�.37).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_provenance.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion evidence source_evidence_literature NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_provenance.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion SIO_000772 21267790 NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_provenance.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion wasDerivedFrom befree-20150227 NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_provenance.
- NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_assertion wasGeneratedBy ECO_0000203 NP379306.RAPymOFnbAtD6hfsNLMWu7Sf3laS2MBSi2gq2yNMkq3yM130_provenance.